Recombinant Single-Chain Variable Fragment Antibodies Directed against *Clostridium difficile* Toxin B Produced by Use of an Optimized Phage Display System

Xiao K. Deng,1† Lance A. Nesbit,2 and K. John Morrow, Jr.1*

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas 79430,1 and Department of Microbiology and Immunology, University of Arizona, Tucson, Arizona 857242

Received 21 October 2002/Returned for modification 25 January 2003/Accepted 20 March 2003

Recombinant antibody cloning and phage display technologies were used to produce single-chain antibodies (scFv) against *Clostridium difficile* toxin B. The starting material was the mouse B cell hybridoma line 5A8, which generates a monoclonal antibody against the toxin. The integrated cloning, screening, and phage display system of Krebber et al. (J. Immunol. Methods 201:35-55, 1997) allowed us to rapidly obtain toxin B-binding scFv sequences derived from the hybridoma cell line. The best candidate scFv sequences, based on preliminary enzyme-linked immunosorbent assay (ELISA) screening data were then subcloned into the compatible expression vector. Recombinant single-chain antibodies were expressed in *Escherichia coli*. A 29-kDa band was observed on polyacrylamide gel electrophoresis as predicted. The expressed product was characterized by immunoblotting and detection with an anti-FLAG antibody. The toxin B-binding function of the single-chain antibody was shown by a sandwich ELISA. The antibody was highly specific for toxin B and did not cross-react with material isolated from a toxin B-negative *C. difficile* strain. The sensitivity of the soluble single-chain antibody is significantly higher than the original monoclonal antibody based on ELISA data and could detect a minimum of 10 ng of toxin B/well. Competitive ELISAs established that the affinity of the 5A8 parent antibody and the best representative (clone 10) of the single-chain antibodies were similar and in the range of 10⁻⁸ M. We propose that recombinant antibody technology is a rapid and effective approach to the development of the next generation of immunodiagnostic reagents.

*Clostridium difficile*, a gram-positive, spore-forming anaerobic bacillus, was first described in 1935 (14), but it was not associated with antibiotic-related diarrhea until the late 1970s (3, 4, 30). *C. difficile* infection can lead to severe complications and currently is the most common cause of nosocomial diarrhea, often adding up to 2 weeks to the length of hospitalization, at an additional cost of $6,000 to $10,000 per case (1, 10, 22, 43, 44, 47, 55).

The organism produces two exotoxins responsible for the pathogenesis of this diarrhea, toxins A and B (12, 39). The most sensitive and specific test available for diagnosis is a tissue culture assay for the cytotoxicity of toxin B, which uses preincubation with a neutralizing antibody to demonstrate specificity (21, 40). This test can detect as little as 10 pg of toxin in stool specimens and has a high sensitivity (94 to 100%) and specificity (99%) (21, 22). However, the test takes 1 to 3 days to complete and requires specialized tissue culture facilities. More recently, enzyme-linked immunosorbent assays (ELISAs) have been developed to detect toxin A and/or toxin B in stool specimens and they have a sensitivity of 71 to 94% and a specificity of 92.5 to 98% (40, 54). Because of the rapidity of testing and ease of performance, ELISAs for toxins A and B are now used most frequently by clinical laboratories for the diagnosis of *C. difficile* infection, but the anti-toxin B antibody employed in the ELISA is difficult to produce and a prime target for genetic manipulation.

During the past decade, advances in antibody cloning technology have greatly facilitated the genetic manipulation of antibody fragments (6, 25). These innovations have permitted the development of a large variety of engineered antibody molecules for research, diagnosis, and therapy with specificities out of reach of conventional antibody technology. Once cloned, it is possible to improve the affinity and specificity of antigen binding by mimicking somatic hypermutation during an immune response (11).

Due to these considerations regarding traditional polyclonal and monoclonal antibody technology for the diagnosis of *C. difficile* infection, we have exploited recombinant antibody and phage display technologies to produce an optimized reagent. We started from the mouse B-cell hybridoma cell line 5A8 (8) which generates a monoclonal antibody against *C. difficile* toxin B. The cloning and phage display system employed was developed by Krebber et al. (27). Using this approach, we have successfully produced highly specific single-chain antibodies directed against *C. difficile* toxin B.

**MATERIALS AND METHODS**

We employed the antibody cloning and phage display system of Krebber et al. (27) with the following modifications.

**Preparation of RNA.** The hybridoma cell line 5A8 was obtained from Meridian Bioscience. Total RNA was extracted from 5 x 10⁶ 5A8 hybridoma cells by using the Trizol total RNA extraction protocol (Gibco BRL) (5).

**First-strand cDNA synthesis.** Five micrograms of total RNA was reversed transcribed in a reaction volume of 33 μl by using separate reactions for light...
chains and heavy chains with the primers specified by Krebber et al. (27) according to the manufacturer’s protocol (first-strand cDNA synthesis kit, catalog no. 27-9261-01; Pharmacia, Piscataway, N.J.).

Cloning of variable fragment of SAA antibody gene. We amplified the entire first frame reading frame (331 bp) into all of the cDNA of interest in the final mixture and added only the PCR primers and Taq DNA polymerase (catalog no. A1661; Promega, San Luis Obispo, Calif.). A cool start protocol was used. We added 40 pmol of LB and LF primer mixes for amplification of the light chain variable domain gene (V\textsubscript{L}) or 40 pmol of HB and HF primer mixes for used. We added 40 pmol of LB and LF primer mixes for amplification of the light chain variable domain gene (V\textsubscript{L}) or 40 pmol of HB and HF primer mixes for amplification of the light chain variable domain gene (V\textsubscript{L}). Taq polymerase (2.5 U) was added directly to the tube kept standing at room temperature for 20 min during the incubation. Elution by competition or by pH change have both proven satisfactory in our hands, as per Krebber et al. (27).

The eluted 1 ml of phage was added to another microcentrifuge tube prepared with 0.5 ml of M Tris (pH 7.4) ready for quick neutralization. Half of this volume (750 µl) was added to 5 ml of mid-log phase (OD\textsubscript{600} of 0.6 to 0.8) cultures of E. coli XL1-Blue. The cells were shaken at 250 rpm at 37°C for 1 h and centrifuged at 3,000 × g for 5 min. The supernatant was carefully discarded, and the cells were resuspended in 500 µl of 2× YT. The entire contents were spread onto 5 NE plates (100 µl per plate) and grown overnight at 26°C. After overnight growth, 1.5 ml of 2× YT medium per plate was added. Next, we scraped off all the colonies and pooled all the cells into Eppendorf tubes. If a broth culture, we then incubated the cells with 50 µl of these cells and grew them to an OD\textsubscript{600} of 1.0. We then proceeded with the phagemid rescue as above. The remainder of the scraped cells were stored at −70°C.

Screening for binders by ELISA. We picked 20 colonies before panning, 6 colonies after the second panning, and 5 colonies after the third panning for the binding test against toxin B. Purified toxin B and cross-reacting protein (CRP; a protein digest isolated from a toxin B-negative strain of C. difficile) were isolated by Meridian Bioscience. For isolation of the CRP, toxin B-negative bacterial strains were grown in brain heart infusion for 3 days. The cultures were harvested by centrifugation. The supernatant was clarified by filtration and passed over a G50 gel filtration column. The first peak is a mixture of proteins containing epitopes which cross-react with unabsorbed polyclonal antibodies raised against toxin B (K. Kozak, personal communication). For isolation of toxin B, positive strains were grown in brain heart infusion for 3 days. Cells were harvested by centrifugation, and the pellet was discarded. The supernatant was clarified by filtration, and a 60% saturated ammonium sulfate cut was made and passed over a DEAE column. The bound toxin was eluted with a salt gradient and further purified by passage through an S300 column. The CRP and the toxin were stored in glycerol buffer at −20°C.

ELISA plates were coated with 10 µg of toxin B/ml (100 µl/well) in PBS at 4°C, and after coating overnight, the wells were rinsed three times with PBS and blocked with 500 µl of 5% dry milk in PBS per well for 2 h at 37°C. For the preparation of phage antibody supernatant to be used as the first antibody in the ELISA, we made 100 clones of XL1-Blue harboring scFv and separated them by heat and filtration. After an OD\textsubscript{600} of 0.5 was reached, we added 2 ml of NE, 1 mM IPTG, and 10¹⁰ PFU of M13K07 helper phage and grew the culture overnight at 26°C in a shaking incubator at 225 rpm. We then collected the phage supernatants by centrifugation at 3,000 × g at 4°C for 10 min. We added an equal volume of 4% dry milk in PBS (MPBS) to the phage supernatants and used them directly in the assay. After blocking with 5% MPBS, wells were rinsed three times with PBS and loaded with 100 µl of phage supernatant prepared as above and incubated for 1 h at room temperature. The plates were washed as described above. We prepared the substrate by mixing 20 µl of citric acid buffer, 8 mg of O-phenylendiamine, and 80 µl of 3% H\textsubscript{2}O\textsubscript{2}, and we incubated the plates for at least 10 min at room temperature in the dark with 150 µl of substrate per well. The reaction was stopped by adding 30 µl of 1 M H\textsubscript{2}SO\textsubscript{4} per well. The plates were read at 492 nm in the 312E ELISA autoreader (Bio-Tek Instruments, Inc., Winooski, Vt.).

Soluble expression of single-chain antibodies. The clones giving the highest signals against toxin B were chosen for further analysis. The scFv in pAK100 was subcloned into the expression vector pAK400 (27), which contains the same SfiI restriction sites as pAK100. The E. coli strain JM83 (which lacks an amber suppressor allowing soluble single-chain antibody expression) was transformed with pAK100 harboring the appropriate scFv candidate. The transformant was plated out on an NE plate, incubated overnight at 26°C, and then stored at 4°C. We then inoculated 50 ml of super broth medium (45) with a single bacterial
colony at 26°C overnight with shaking at 250 rpm. We next inoculated 1 liter of super broth medium with this 50 ml preculture and shook the culture at 26°C at 200 rpm. To induce antibody expression, we grew the cultures to an OD_{600} of 0.5, added 0.25 ml of 1 M IPTG (final concentration, 0.5 mM), and continued shaking until the culture reached the stationary phase. Usually, this was within 4 to 6 h after induction, when the final OD_{600} reached 3 to 6. We then harvested the cells by centrifugation (8,000 × g, 10 min, 4°C). To prepare the whole-cell extract, we resuspended the cell pellet in 20 ml of HEPEs extraction buffer (20 mM HEPEs and 0.5 M NaCl adjusted to pH with NaOH) (53), disrupted the cells in a French press, added DNase I to a final concentration of 10 μg/ml, and then centrifuged it at 10,000 g for 10 min, carefully transferring the supernatant containing the single-chain antibody. The supernatant was then digested by Sfi I digestion, one is pAK100 DNA, which is about a 4-kb band on the gel, and another is the scFv insert, which is a 750-kb band on the gel as predicted.

**FIG. 1.** Agarose gels showing the sequence of cloning of the variable heavy and light chain antibody genes from the hybridoma line 5A8. Lanes 1, 4, and 9 are the DNA ladders. Lanes 2 and 3 are the light and heavy chain DNAs, respectively. Lanes 5 and 6 are assembly PCR products (the complete scFv DNA). Lanes 7 and 8 are two different samples of the recombinant expression cassette after Sfi I digestion. After amplification from cDNA, the V_{H} and V_{L} DNA appeared on the 1% agarose gel as sharp bands at ca. 400 bp. The V_{H} and V_{L} were then combined into a single-chain fragment through the following assembly PCR, which is shown in lanes 5 and 6 as a 750-bp band. This scFv product was further cloned into the phage display vector pAK100 to form the single-chain antibody phage display cassette. As shown in lanes 7 and 8, the display cassette is comprised of two fragments after Sfi I digestion, one is pAK100 DNA, which is about a 4-kb band on the gel, and another is the scFv insert, which is a 750-kb band on the gel as predicted.

Electrophoresis and immunoblotting. Bacterial extracts were mixed with sample buffer with sodium dodecyl sulfate (SDS) and dithiothreitol and electrophoresed by SDS-polyacrylamide gel electrophoresis (PAGE) (29) on a 10% polyacrylamide gel. Proteins were electroblotted onto nitrocellulose to be assayed by Western blot analysis (53). For immunostaining, blots were blocked in Tris-buffered saline (TBS) containing 5% nonfat dry milk and incubated with an anti-FLAG antibody diluted 1:2,000 in TBS with 1 mM CaCl_{2} at room temperature for 30 min. Blots were washed three times with TBS containing 1 mM CaCl_{2} and incubated in HRP-conjugated goat anti-mouse antibodies at a ratio of 1:1,000 dilution. The developed plates were read at 490 nm in the ELISA autoreader.

Cloning of variable fragment of antibody genes to form the 5A8 single-chain antibody phage display cassette. Total RNA preparation from the hybridoma line 5A8 and cDNA synthesis were performed as described above. The use of the whole-cDNA reaction mixture for PCR amplification of the variable light and heavy chain genes allowed us to obtain sufficient amounts of products for cloning. The light and heavy chains both generated a sharp band at around 400 bp as predicted previously (27). The antibody heavy and light chain DNA were subsequently joined into a single-chain fragment (scFv) by a (Gly_{4} Ser)_{3} linker sequence. The scFv could be seen on the agarose gel as a ca. 750-bp band. After purification, the scFv was then digested by Sfi I and ligated into the phage display vector pAK100 to form the cassette (Fig. 1).
Panning to select the phages displaying toxin B-positive recombinant antibodies. The panning procedure was used to selectively capture toxin B-positive recombinant phage with toxin B bound to an immunotube. The recombinant vector pAK100 was transformed into XL1-Blue and rescued by the M13K07 helper phage. Then the single-chain antibody was expressed as an anchored protein on the head of the phage particle. Those phage antibodies were subjected to biopanning. Three panning cycles have been carried out. The phage antibody pools prepared after 0, 1, 2, and 3 rounds of panning were tested for toxin B-specific binding in a phage ELISA. The phage ELISA results are shown in Fig. 2, in which the ELISA signal increases with each round of panning. The phage antibody gave a very weak signal against toxin B before panning with an OD490 of only 0.372. The OD490 increased as a function of the number of rounds of panning: 0.68 after the first panning, 1.41 after the second panning, and 1.78 after the third panning. The bacteriophage containing the nucleotide sequences encoding a functional scFv sequence were enriched by repeating the biopanning.

Based on these findings, we chose those individual clones which produce toxin B-binding phage antibody and used them to express soluble scFv antibody. For this purpose, 20 individual colonies were chosen prior to panning, 6 colonies were picked after the second panning, and 5 colonies were chosen after the third panning. They were grown and infected by M13K07 helper phage. The sequences expressed in the phage head from those single colonies were then screened for binding with toxin B by the phage ELISA (Fig. 3). The percentage of clones producing phage with specific toxin B-binding sequences increases as a function of the number of rounds of biopanning. It is 35% (7 of 20) before panning, 100% (6 of 6) after second panning, and 100% (5 of 5) after the third panning. The strongest binders were chosen for further analysis: clone 10 from round 0, clone 6 from round 2, and clone 4 from round 3. These three clones were then processed to generate soluble, single-chain antibodies.

Expression of soluble antibody from cloned scFv fragments. Three scFv sequences which give the strongest ELISA signals against toxin B were subcloned into the expression vector pAK400. After IPTG induction, both periplasm and whole-cell fractions were prepared to determine the location of the recombinant proteins. For further characterization, the culture extracts were subjected to reducing SDS-PAGE, immunoblotted, and probed with the anti-FLAG antibody, which recognizes the N-terminal FLAG tag fused to the antibody sequence. Only recombinant proteins in the whole-cell and periplasmic fractions demonstrated reactivity with the anti-FLAG antibody at the predicted 29-kDa molecular mass, the monomer form of the scFv antibody (Fig. 4, lanes 4 and 7). This species appears in the periplasm. Possibly due to the oligo-histidine tags in the C-terminal end of the scFv fragment, dimerized molecules also appeared in the immunoblot, at double the size of the scFv antibody (Fig. 4, lanes 4 and 6). The dimerized form was seen mainly in the whole-cell extract. The FLAG-tagged recombinant proteins were not observed in the uninduced culture or in the vector without the insert. Periplasmic fractions containing the soluble FLAG-tagged recombinant antibodies were purified for all further experiments, including antibody evaluation through ELISA.

Sandwich ELISA comparison with scFv antibodies and 5A8 hybridoma supernatant as the capture antibodies. The puri-

FIG. 2. ELISA signal from phage pools as a function of the round of the biopanning cycle. Phage antibodies after 0, 1, 2, and 3 rounds of panning were tested in parallel for their antibody activity against 50/50 serially diluted toxin B or CRP, starting from 1 μg/well. The bound phage was detected with an anti-m13 antibody. The CRP antigen was coated on the plates in the same way as toxin B. Binding levels to wells coated with toxin B or CRP for pooled phage after rounds 0 (rows 1 and 2), 1 (rows 3 and 4), 2 (rows 5 and 6), and 3 (rows 7 and 8) are shown.
fied soluble antibodies were used in a capture assay similar to that employed in the Meridian Bioscience diagnostic kits. The initial concentration of the antibody in the sandwich ELISA was determined, and the same amounts of all the antibodies were tested at different serial concentrations. At the 1:32 dilution (equivalent to 15 ng of IgG antibody/µl), the hybridoma supernatant monoclonal antibody no longer produced a measurable signal. However, the scFv antibody retained the ability to capture measurable antigen down to less than 10 ng of toxin B (Fig. 5). Under these conditions, all of the single-chain antibodies from different clones gave values that were substantially higher than the 5A8 monoclonal antibody. Low nonspecific reactivity was observed with the blank vector.

**ELISAs for affinity measurements.** We evaluated the comparative affinities of the 5A8 parent hybridoma and the best representative of our scFv antibodies, based on the initial ELISA data. We found that the comparative affinity of the clone 10 scFv and the 5A8 parent hybridoma were the same within the range of experimental error, ca. $10^{-10}$ M (Fig. 6).

**DISCUSSION**

There is a growing need in clinical microbiology for diagnostic methods that do not rely upon culturing and cytotoxicity assays. Immunological methods are widely used, as they are rapid and relatively economical. In the last few years, a variety of molecular approaches to antibody development have become widely available. Generating polyclonal antibodies is time consuming, requires large animals, and may be subject to the vagaries of biological variability. While hybridoma technology represents a considerable advance, it is slow, expensive, and labor intensive and it may require many rounds of evaluation to achieve a satisfactory antibody. However, phage display technology when combined with cloning of antibody genes, can eliminate these drawbacks.

Recombinant antibody cloning coupled with phage display (7) is a relatively recent approach to the issue of developing better diagnostic reagents. Phage display was proposed in the mid-1980s by Smith (49). In contrast to the conventional hybridoma technology (24) for the production of monoclonal antibodies, phage display is not based on immortalization and cloning of the antibody-producing lymphocytes themselves. Rather, screening of antibody libraries can recreate the vertebrate immune system in vitro.

An enormous sample (up to $10^9$ clones) can be isolated from a single immunized animal, and the affinity of these antibodies...
can be enhanced by in vitro affinity maturation (13). A prerequisite for the success of phage antibody display techniques is the reliable cloning of functional immunoglobulin genes. A DNA library of antibody sequences may be created from spleen cells from unimmunized animals or animals immunized with antigens or from hybridoma cells (if available) (32). In the present study, we cloned the variable light and heavy chain antibody fragments from the 5A8 hybridoma line, which generates a monoclonal antibody against toxin B. We also have available spleen cells taken directly from toxin B-immunized mice, which may provide a better representation of the possible antibody gene repertoire (16, 36, 52). But the most direct approach is to start from a hybridoma rather than by screening combinatorial libraries. The latter approach was reported to frequently result in the production of scFvs with low solubility and reduced binding affinities in the range $10^{-5}$ to $10^{-7}$ M, which are unsuitable for diagnostic use.

For this investigation, we employed the cloning and phage display system of Krebber et al. (27), which was quite satisfactory. The extended primer set can incorporate all of the mouse $V_H$ and $V_L$ sequences collected in the Kabat database (18) and can be modified to accommodate other species as well. In

FIG. 5. Sandwich ELISA of equivalent amounts of soluble scFv antibodies compared with 5A8 hybridoma supernatant. Lines are as indicated on the figure. Antibody concentrations were constant, as indicated in Methods and Materials. The toxin B concentration was serially diluted.

FIG. 6. Competition ELISA to determine relative affinity for scFv clone 10 and 5A8 IgG. The relative affinities were determined by inhibition ELISA with toxin B as the competing antigen.
addition, the system included a FLAG peptide introduced at the N terminus of the V\text{L} chain for purification by commercial kits (19, 23) and SOE-PCR assembly from two rather than three pieces (31). Incorrect overlaps during assembly PCR were prevented by four (Gly, Ser) repeats, encoded by different codons (27, 50), and S\text{fi} restriction sites that produce two different sticky ends at the same time (53). This is the only enzyme necessary for directional cloning of the scFv fragments into the phage display vector pAK100, preventing self-dimerization by either insert or vector (17). Other useful features of the system are described by Krebber et al. and in related papers (26, 27, 37, 48).

In our hands, the amount of light and heavy chain DNA was the critical factor for success of the assembly PCR. In order to obtain enough light and heavy chain DNA, we used the entire first-strand reaction for amplification. Both light and heavy chain DNA show up as two sharp bands of 400 bp on agarose gels. These are of the anticipated molecular weights, which were confirmed by DNA sequencing of scFv portions of the genes (Fig. 6). The concentration of both DNAs has to be determined very carefully in order to keep their amounts the same, which is critical for the success of the subsequent SOE-PCR. For us, the most accurate measure was obtained by running gel electrophoresis and correlating the intensity of bands with the known quantities on the DNA ladder. These amounts were assembled in the subsequent SOE-PCR, which yielded the single-chain variable fragment DNA of 750 bp. More than one assembly PCR was performed to obtain enough pure scFv DNA.

It appears that the function of the panning was to eliminate nonfunctional sequences from the original pool, since the ELISA performance of individual clones from later pannings did not improve. Rather, the average value of the pool increased due to the elimination of nonfunctional members. This bodies well for the future success of the many options that are available to us for improving our scFv performance.

The single chain antibody was expressed on the phage as a membrane-anchored protein. This allows us to perform antibody selection very efficiently and to isolate the best candidate scFv antibodies through biopanning. Once the best antibody candidate was chosen, the sequences were transferred into the appropriate expression plasmid for large-scale expression. Phage antibodies showed high specificities for toxin b, either as a component of the phage or as soluble antibodies, without cross-reaction with the CRP. We determined the best three candidates in our sample: from round 0, clone 10; from round 2, clone 6; from round 3, clone 4. These sequences were moved from the pAK100 vector to the pAK400 vector for expression.

For soluble scFv antibody expression, the nonsuppressed \textit{E. coli} host JM83 was used. The soluble scFv antibody was visualized as a 29-kDa band by PAGE. During the process of generating the light chain and the heavy chain, the behavior of the scFv could be altered from that of the parental IgG, which may explain the superior performance of the scFv over the hybridoma supernatants. However, the binding of the single-chain antibody was determined by its performance in the sandwich ELISA, in order to duplicate the conditions employed in the Meridian Bioscience kit for toxin B diagnosis.

As shown by the sandwich ELISA data, antibody performance has been improved compared with the starting monoclonal antibody. The ELISA signal from clone 6 is much higher than the 5A8 monoclonal antibody, but the binding between the scFv and toxin is highly specific, as evidenced by the lack of cross-reactivity with the CRP. Furthermore, there is no cross-reaction between the toxin B and the bacterial extract containing the blank pAK400 vector without the scFv insert. These observations are especially striking in light of the fact that we have not yet mutagenized or shuffled the original 5A8 sequences. Clearly, if these first investigations have provided a satisfactory reagent, future manipulations potentially could produce a reagent with extremely high binding affinity.

The competitive ELISAs demonstrate conclusively that the scFvs are specific for toxin B and that the comparative affinities are similar to that of the parent monoclonal antibody (ca. $10^{-8}$). Our scFv should lend itself to favorable improvements through mutagenesis by using error-prone PCR, allowing even stronger binding affinities to be obtained.

It should be noted that we used our single-chain antibodies as the capture antibody in the ELISA procedure, although under these conditions the small scFv molecule can undergo partial denaturation (A. Plückthun, personal communication) which should lower its performance. We believe that much of the activity observed is due to spontaneous dimerization, as revealed by the immunoblot. The phenomenon of dimerization or even higher oligomerization of single-chain antibody Fv fragments has been reported previously (2). These observations are a manifestation of the phenomenon of domain swapping, which is defined as one domain of a monomeric protein being replaced by the same domain of a second, related monomeric protein chain. The scFv fragment was found to form a dimer after freezing and thawing. Additionally, the expression conditions can play a role. The difference in a dimeric fraction resulting from the expression method can also be best explained by a trapped dimer during periplasmic expression. Under these conditions, the dimeric form is favored, probably due to the at least 500-fold-higher concentration during folding in the periplasm. Other factors, such as ionic strength and pH, were shown to influence the rate of the dimer-to-monomer conversion (2). The noncovalent association of two single-chain Fv fragments leads to a considerable gain in binding ability, and thus, sensitivity is observed to be increased for all dimerization constructs compared to the monomeric scFv fragment. This is consistent with the simultaneous binding of two or even more binding sites to the same surface. It is also probably the most important reason why our antibody has better performance in ELISA than the original 5A8 antibody.

The amount of toxin B we employed in our detection techniques was 10 \textmu g/ml. By using phage display, we are allowing for multiple interactions of the scFv on the surface of the bacteriophage with the toxin B. This allows for greater sensitivity for the antigen, so detection of the toxin within the patient stool in the presence of other bacteria and inhibitory factors can be enhanced. Using purified samples enabled us to develop the antibody, which can be altered for greater affinity if necessary for the detection of \textit{C. difficile} within clinical samples.

We employed an extract from a toxin B-negative strain of \textit{C. difficile} to determine if the phage scFv could cross-react with nontoxin epitopes. We recognize that other bacterial components such as other species of \textit{Clostridium} or toxin B-negative
C. difficile strains, which has had the toxin B rescued by plasmid expression, should be used to confirm 5A8 specificity. It has been shown that C. difficile toxin B works in conjunction with toxin A to produce pathological effects on the host. toxin B is also capable of producing virulent effects alone as well. Therefore, ensuring the specificity of 5A8 can enable us to target C. difficile present in the gut, even if the strain is only producing toxin B and not toxin A, which is capable of conferring pathological effects to the patient.

We are currently designing diabodies and other structural modifications of our original starting material, which we anticipate will further augment the performance of our recombinant antibody toxin B detection system (2, 19).

These data establish a proof of principle demonstrating that the system is working optimally, and we now have available soluble, single-chain antibodies against the C. difficile toxin, which will serve as a starting point for further investigations. We believe this strategy will result in antibodies with greater levels of sensitivity, by using rational design and gene shuffling protocols (9, 13, 15, 20, 28, 35, 41, 44, 50).

ACKNOWLEDGMENTS

This work was supported by a contract from Meridian Bioscience, Cincinnati, Ohio, and by the Howard Hughes Medical Research Institute Texas Tech Undergraduate Research Training program.

REFERENCES

1. Anand, A., B. Bashey, T. Mir, and A. E. Glatt. 1994. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am. J. Gastroenterol. 89:519–523.
2. Arndt, K., K. M. Muller, and A. Pluckthun. 1992. Antibody-associated pseudomonosaccharides as toxins for toxin-producing clostridia. N. Engl. J. Med. 328:531–534.
3. Berger, S. L., and J. M. Chirgwin. 1985. Isolation of RNA. Methods Enzymol. 103:3–13.
4. Boss, M. A., J. H. Kenth, C. R. Wood, and J. S. Emtage. 1978. Cladaminycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136:701–705.
5. Bartlett, J. G., T. W. Chang, M. Gurwith, S. L. Gorbach, and A. B. Onderdonk. 1978. Antibiotic-associated pseudomonosaccharides as toxins for toxin-producing clostridia. N. Engl. J. Med. 328:531–534.
6. Blackton, T. H. P. Hoonenboom, A. D. Griffiths, and G. Winter. 1991. Making antibody fragments using phage display libraries. Nature 352:624–628.
7. Cousin, R. T., M. A. manicci, J. C. Chesney, and G. M. Winter. 1994. Characterization of six murine monoclonal antibodies specific for toxin B of Clostridium difficile. Hybridoma 13:147–152.
8. Cramer, R., and M. Suter. 1993. Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene 137:69–75.
9. Djuricic, T., M. J. Ryan, D. M. Fleming, and P. G. Wall. 1996. Infectious intestinal disease in elderly people. Commun. Dis. Rep. Wkly. 19:R107–R112.
10. Gram, H., L. A. Marcon, and C. F. Barbas, T. A. Collet, R. A. Lerner, and A. S. Kang. 1992. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. Natl. Acad. Sci. USA 89:3576–3580.
11. Grossmann, E. M., W. E. Longo, D. L. Kaminski, G. S. Smith, C. E. Murphy, R. L. Durham, M. J. Shapiro, J. G. Norma, and J. E. Mazuzki. 2000. Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes. J. Surg. Res. 88:165–172.
12. Gunneronsson, E., K. Nord, M. Uhlen, and P. Nygren. 1999. Affinity maturation of a TGF DNA polymerase specific antibody by helix shuffling. Protein Eng. 12:873–878.
13. Hall, I. C., and E. O’Toole. 1935. Intestinal flora in newborn infants with description of a new pathogenic anaerobe, Bacillus difficile. Am. J. Dis. Child. 49:390–402.
14. Hooenboom, H. R., A. D. Griffiths, K. S. Johnson, D. J. Chiswell, P. Hud-
44. Ryu, D. D., and D. H. Nam. 2000. Recent progress in biomolecular engineering. Biotechnol. Prog. 16:2–16.
45. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
46. Samore, M. H., L. Venkataraman, P. C. DeGirolami, R. D. Arbeit, and A. W. Karchmer. 1996. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am. J. Med. 100:32–40.
47. Sastry, L., M. Alting-Mees, W. D. Huse, J. M. Short, J. A. Sorge, B. N. Hay, K. D. A. Janda, S. J. Benkovic, and R. A. Lerner. 1989. Cloning of the immunological repertoire in Escherichia coli for generation of monoclonal catalytic antibodies: construction of a heavy chain variable region-specific cDNA library. Proc. Natl. Acad. Sci. USA 86:5728–5732.
48. Skerra, A., and A. Plückthun. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038–1041.
49. Smith, G. P. 1985. Filamentous fusion phage: novel expression vectors that display clone antigen on the virion surface. Science 228:1315–1317.
50. Stoop, A. A., L. Jespers, I. Lasters, E. Eldering, and H. Pannekoek. 2000. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-1). J. Mol. Biol. 301:1135–1147.
51. Towbin, H., T. Stachelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350–4354.
52. Vaughan, T. J., A. J. Williams, K. Pritchard, J. K. Osbourn, A. R. Pope, J. C. Earnshaw, J. McCafferty, R. A. Hodits, J. Wilton, and K. S. Johnson. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14:309–314.
53. Wentzell, L. M., T. J. Nobbs, and S. E. Halford. 1995. The SfiI restriction endonuclease makes a four-strand DNA break at two copies of its recognition sequence. J. Mol. Biol. 248:581–595.
54. Whittier, S., D. S. Shapiro, and W. F. Kelly. 1993. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases. J. Clin. Microbiol. 31:2861–2865.
55. Wilcox, M. H., J. G. Cunniffe, C. Trundle, and C. Redpath. 1996. Financial burden of hospital-acquired Clostridium difficile infection. J. Hosp. Infect. 34:23–30.